AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31155474 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Group (calorie-tracking DSM app)
Number of subjects: 41
Study 31155474 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo Group (photo DSM app)
Number of subjects: 41
Study 31155474 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study 27049826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (up to 3 times daily for 6 months)
Number of subjects: 202
Study 27049826 — intervention group
Group type: COMPARATOR
Intervention: Diacetylmorphine (up to 3 times daily for 6 months)
Number of subjects: 202
Study 27049826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 202
Study 27049826 — intervention group
Group type: COMPARATOR
Intervention: Diacetylmorphine
Number of subjects: 202
Study 25057155 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Fe with water
Number of subjects: 32
Study 25057155 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Fe with food
Number of subjects: 32
Study 25057155 — intervention group
Group type: COMPARATOR
Intervention: 6 mg Fe with food
Number of subjects: 32
Study 25057155 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Fe without food
Number of subjects: 32
Study 22192729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aflibercept (4 mg/kg every 2 weeks)
Number of subjects: 55
Study 22192729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 22192729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aflibercept
Number of subjects: 55
Study 20184211 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05%
Number of subjects: 217
Study 20184211 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 217
Study 17097649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate 50 mg/m(2) administered on days 0 and 4; additional doses on day 7 and/or day 11 if hCG levels did not decrease by 15%
Number of subjects: 101
Study 16199417 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection thoracic paravertebral block with bupivacaine 0.375% and adrenaline 1:200 000 0.4 ml kg(‐1) plus i.v. patient‐controlled analgesia (PCA) with morphine
Number of subjects: 40
Study 16199417 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with back puncture without injection and morphine PCA
Number of subjects: 40
Study 12115221 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-based imaging technique
Number of subjects: 22
Study 10619912 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric adenocarcinoma samples
Number of subjects: 85
Study 10619912 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse adenocarcinomas
Number of subjects: 85
Study 10619912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal type gastric adenocarcinoma
Number of subjects: 85
Study 10619912 — intervention group
Group type: COMPARATOR
Intervention: Normal gastric mucosa specimens
Number of subjects: 85
Study 7478700 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral tramadol
Number of subjects: 144
Study 7478700 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral tramadol
Number of subjects: 144
Study 7478700 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg paracetamol + 60 mg codeine (active control)
Number of subjects: 144
Study 7478700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 1545135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingosines (D-sphingosine, D,L-sphinganine, 4-D-hydroxysphinganine, oleoyl-sphingosine, N,N-dimethylsphingosine)
Number of subjects: 0
Study 1545135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingosines (erythro- and threo-isomers)
Number of subjects: 0
Study 6366276 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 12
Study 6366276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30762613 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 ECG replicates within a 3‐minute window
Number of subjects: 100
Study 30762613 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 ECG replicates
Number of subjects: 100
Study 30762613 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration‐effect analysis
Number of subjects: 100
Study 29119559 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous methylprednisolone (MP) 125 mg
Number of subjects: 70
Study 29119559 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 70
Study 26850208 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person-shooter game (ShotG)
Number of subjects: 20
Study 26850208 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery game (SurgG)
Number of subjects: 20
Study 26850208 — intervention group
Group type: EXPERIMENTAL
Intervention: Racing game (RaceG)
Number of subjects: 20
Study 26850208 — intervention group
Group type: COMPARATOR
Intervention: Control and/or nongaming (ContG)
Number of subjects: 20
Study 23828016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intra-articular injection
Number of subjects: 80
Study 23828016 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided intra-articular injection
Number of subjects: 80
Study 20489027 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg twice daily coadministered with S/GSK1349572 30 mg once daily for 14 days
Number of subjects: 31
Study 20489027 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 600/100 mg twice daily coadministered with S/GSK1349572 30 mg once daily for 14 days
Number of subjects: 31
Study 20489027 — intervention group
Group type: COMPARATOR
Intervention: S/GSK1349572 30 mg once daily
Number of subjects: 31
Study 19288566 — intervention group
Group type: COMPARATOR
Intervention: e‐CE intervention
Number of subjects: 15
Study 19288566 — intervention group
Group type: COMPARATOR
Intervention: multicomponent e‐CE intervention
Number of subjects: 15
Study 17106401 — intervention group
Group type: EXPERIMENTAL
Intervention: COAS G200 Aberrometer
Number of subjects: 2394
Study 17106401 — intervention group
Group type: COMPARATOR
Intervention: Canon RK‐F1 Autorefractor
Number of subjects: 2394
Study 15095653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment of all cardiovascular risk factors
Number of subjects: 15
Study 15095653 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐intensive group
Number of subjects: 15
Study 11342895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 378
Study 11342895 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin 2.5 mg twice daily (increased to 5 mg after 2 weeks)
Number of subjects: 378
Study 11342895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 378
Study 11342895 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 378
Study 9204803 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Waffle (commercial heel elevation device)
Number of subjects: 52
Study 9204803 — intervention group
Group type: COMPARATOR
Intervention: Hospital pillows
Number of subjects: 52
Study 9204803 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Waffle
Number of subjects: 52
Study 9204803 — intervention group
Group type: COMPARATOR
Intervention: Pillow
Number of subjects: 52
Study 1539476 — intervention group
Group type: COMPARATOR
Intervention: Propofol anaesthesia (Group G)
Number of subjects: 59
Study 1539476 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical blockade with midazolam (Group R)
Number of subjects: 59
Study 1539476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine concentration (Group R)
Number of subjects: 59
Study 1539476 — intervention group
Group type: COMPARATOR
Intervention: p-deletion score (Group G)
Number of subjects: 59
Study 3886311 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with penicillin/pivampicillin
Number of subjects: 474
Study 3886311 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 474
Study 3886311 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with a history of pelvic inflammatory disease (PID)
Number of subjects: 474
Study 3886311 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with postabortal infection
Number of subjects: 474
Study 30995174 — intervention group
Group type: COMPARATOR
Intervention: Pelvic Radiation Therapy (RT) at 45 to 50.4 Gy over 5 weeks
Number of subjects: 601
Study 30995174 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Cuff Brachytherapy plus Paclitaxel/Carboplatin (VCB/C)
Number of subjects: 601
Study 29374733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia - single-dose
Number of subjects: 56
Study 29374733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia - repeated-dose
Number of subjects: 56
Study 29374733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) analgesia - continuous infusion
Number of subjects: 56
Study 29374733 — intervention group
Group type: COMPARATOR
Intervention: No RSB (control group)
Number of subjects: 56
Study 26045170 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg • kg(-1) anhydrous caffeine)
Number of subjects: 10
Study 26045170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial sweetener)
Number of subjects: 10
Study 25440232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone injection gun (BIG)
Number of subjects: 107
Study 25440232 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ‐IO
Number of subjects: 107
Study 25440232 — intervention group
Group type: EXPERIMENTAL
Intervention: Jamshidi
Number of subjects: 107
Study 22211640 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1415
Study 22211640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1415
Study 22211640 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL tertile
Number of subjects: 1415
Study 22211640 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL
Number of subjects: 1415
Study 20645509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric 0.5% bupivacaine (3 ml)
Number of subjects: 60
Study 20645509 — intervention group
Group type: COMPARATOR
Intervention: Isobaric 0.5% bupivacaine (3 ml)
Number of subjects: 60
Study 18541900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 670
Study 18541900 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 670
Study 15955951 — intervention group
Group type: EXPERIMENTAL
Intervention: NT 201 (70 to 300 U)
Number of subjects: 463
Study 15955951 — intervention group
Group type: COMPARATOR
Intervention: BOTOX (70 to 300 U)
Number of subjects: 463
Study 11807147 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP plus rituximab
Number of subjects: 399
Study 11807147 — intervention group
Group type: COMPARATOR
Intervention: CHOP alone
Number of subjects: 399
Study 10075337 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral biotin (2.1 micromol)
Number of subjects: 6
Study 10075337 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral biotin (8.2 micromol)
Number of subjects: 6
Study 10075337 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral biotin (81.9 micromol)
Number of subjects: 6
Study 10075337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous biotin (18.4 micromol)
Number of subjects: 6
Study 10075337 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of biotin (oral and intravenous)
Number of subjects: 6
Study 10075337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous biotin and largest oral dose
Number of subjects: 6
Study 7669468 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 2124311 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anaesthesia with PDA and intubation
Number of subjects: 20
Study 2124311 — intervention group
Group type: COMPARATOR
Intervention: Balanced fentanyl analgesia
Number of subjects: 20
Study 434682 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drug regimen (beta-lactam antibiotic)
Number of subjects: 25
Study 434682 — intervention group
Group type: COMPARATOR
Intervention: Combination antibiotic regimen (beta-lactam antibiotic + aminoglycoside)
Number of subjects: 25
Study 31690187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at rest at baseline
Number of subjects: 48
Study 27359179 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 28
Study 27359179 — intervention group
Group type: COMPARATOR
Intervention: Very light-intensity exercise
Number of subjects: 28
Study 25578255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab or aflibercept (fixed regimen for 48 weeks followed by flexible regimen until week 96)
Number of subjects: 1240
Study 25578255 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible pro re nata (PRN) regimen after fixed regimen
Number of subjects: 1240
Study 23667587 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Biomarker Disease Activity (MBDA) test with educational materials
Number of subjects: 81
Study 23667587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MBDA test information)
Number of subjects: 81
Study 21857273 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection sciatic nerve block (Fs group)
Number of subjects: 90
Study 21857273 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve block (FCS group)
Number of subjects: 90
Study 21857273 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia via femoral nerve catheter alone (F group)
Number of subjects: 90
Study 21857273 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (F, Fs, FCS)
Number of subjects: 90
Study 18718986 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept added to methotrexate monotherapy
Number of subjects: 210
Study 18718986 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate added to etanercept monotherapy
Number of subjects: 210
Study 18718986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (etanercept + methotrexate)
Number of subjects: 210
Study 17300874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 78
Study 17300874 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation
Number of subjects: 78
Study 15487477 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga group (20 sessions)
Number of subjects: 19
Study 15487477 — intervention group
Group type: COMPARATOR
Intervention: Control group (cooperative activities)
Number of subjects: 19
Study 15487477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 15487477 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga group
Number of subjects: 19
Study 15487477 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga group (home practice)
Number of subjects: 19
Study 15487477 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion Logger Actigraph
Number of subjects: 19
Study 11307743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulization of iloprost
Number of subjects: 18
Study 11307743 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulization of iloprost
Number of subjects: 18
Study 9568470 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 21
Study 9568470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8047708 — intervention group
Group type: EXPERIMENTAL
Intervention: Shooting at 8-ft basket
Number of subjects: 74
Study 8047708 — intervention group
Group type: COMPARATOR
Intervention: Shooting at 10-ft basket
Number of subjects: 74
Study 8047708 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy prior to shooting at 8-ft basket
Number of subjects: 74
Study 8047708 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy prior to shooting
Number of subjects: 74
Study 3132364 — intervention group
Group type: EXPERIMENTAL
Intervention: FreAmine
Number of subjects: 51
Study 3132364 — intervention group
Group type: EXPERIMENTAL
Intervention: F080
Number of subjects: 51
Study 31645288 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anaesthesia‐analgesia (paravertebral blocks and propofol)
Number of subjects: 2132
Study 31645288 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (sevoflurane) and opioid analgesia
Number of subjects: 2132
Study 31645288 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anaesthesia‐analgesia
Number of subjects: 2132
Study 31645288 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 2132
Study 28196046 — intervention group
Group type: EXPERIMENTAL
Intervention: Test (new oral formulation of levosulpiride, tablet 25 mg)
Number of subjects: 32
Study 28196046 — intervention group
Group type: COMPARATOR
Intervention: Reference (commercially available formulation, tablet 25 mg)
Number of subjects: 32
Study 25355797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted whole‐virus G9 lineage H9N2 influenza virus vaccine (doses ranging from 3.75 to 45 μg of hemagglutinin antigen)
Number of subjects: 0
Study 25355797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted whole‐virus G9 lineage H9N2 influenza virus vaccine
Number of subjects: 0
Study 24292351 — intervention group
Group type: EXPERIMENTAL
Intervention: BOO (1(3)‐behenoyl‐2,3(1)‐dioleoyl‐rac‐glycerol) intake of 2.46 g/day for 7 days
Number of subjects: 14
Study 24292351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soft cookies containing margarine without BOO)
Number of subjects: 14
Study 24292351 — intervention group
Group type: EXPERIMENTAL
Intervention: BOO (1(3)‐behenoyl‐2,3(1)‐dioleoyl‐rac‐glycerol)
Number of subjects: 14
Study 20886556 — intervention group
Group type: EXPERIMENTAL
Intervention: LOH on 17p13.1
Number of subjects: 37
Study 20886556 — intervention group
Group type: EXPERIMENTAL
Intervention: LOH on 4q
Number of subjects: 37
Study 20886556 — intervention group
Group type: EXPERIMENTAL
Intervention: LOH on 8p
Number of subjects: 37
Study 18720880 — intervention group
Group type: COMPARATOR
Intervention: Moderate and severe OSAHS
Number of subjects: 60
Study 18720880 — intervention group
Group type: COMPARATOR
Intervention: Mild OSAHS
Number of subjects: 60
Study 16443423 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-containing groups
Number of subjects: 221
Study 16443423 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen-only group
Number of subjects: 221
Study 12763175 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated Protein C (alpha‐drotrecogin)
Number of subjects: 0
Study 12763175 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant TFPI
Number of subjects: 0
Study 12763175 — intervention group
Group type: EXPERIMENTAL
Intervention: AT concentrates
Number of subjects: 0
Study 10480191 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of cerivastatin sodium once daily
Number of subjects: 73
Study 10480191 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg of cerivastatin sodium once daily
Number of subjects: 73
Study 10480191 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of cerivastatin sodium
Number of subjects: 73
Study 10480191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results of 0.3 mg and 0.15 mg groups
Number of subjects: 73
Study 8620266 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider prompt/reminder
Number of subjects: 98
Study 8620266 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted treatment planner
Number of subjects: 98
Study 8620266 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive patient education/therapy
Number of subjects: 98
Study 8620266 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient prompt/reminder
Number of subjects: 98
Study 1906020 — intervention group
Group type: EXPERIMENTAL
Intervention: Flare-up ovarian stimulation protocol for patterns A and B
Number of subjects: 80
Study 1906020 — intervention group
Group type: EXPERIMENTAL
Intervention: Early luteal phase Lupron protocol for pattern C
Number of subjects: 80
Study 1906020 — intervention group
Group type: EXPERIMENTAL
Intervention: High pure FSH flare-up protocol for pattern D
Number of subjects: 80
Study 7065943 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% DMC
Number of subjects: 0
Study 7065943 — intervention group
Group type: EXPERIMENTAL
Intervention: 9% DMC
Number of subjects: 0
Study 7065943 — intervention group
Group type: COMPARATOR
Intervention: 1% pilocarpine
Number of subjects: 0
Study 31344257 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual stimulation
Number of subjects: 160
Study 31344257 — intervention group
Group type: COMPARATOR
Intervention: Histamine iontophoresis
Number of subjects: 160
Study 31344257 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 160
Study 29807661 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-induced cortisol reactivity
Number of subjects: 0
Study 29807661 — intervention group
Group type: COMPARATOR
Intervention: No-stress control
Number of subjects: 0
Study 29807661 — intervention group
Group type: COMPARATOR
Intervention: Cortisol non-responders
Number of subjects: 0
Study 28275044 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue Hb 301 devices
Number of subjects: 2846
Study 28275044 — intervention group
Group type: EXPERIMENTAL
Intervention: Device operators
Number of subjects: 2846
Study 26520401 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral artesunate at 2.4 mg/kg at H0, H12, H24 and then once daily (ARTES)
Number of subjects: 116
Study 26520401 — intervention group
Group type: COMPARATOR
Intervention: Loading dose of quinine base at 16.6 mg/kg followed by maintenance dose of 8.3 mg/kg (QLD)
Number of subjects: 116
Study 26520401 — intervention group
Group type: COMPARATOR
Intervention: 8.3 mg/kg quinine base every 8 hours (QNLD3)
Number of subjects: 116
Study 26520401 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg/kg quinine base every 12 hours (QNLD2)
Number of subjects: 116
Study 24455828 — intervention group
Group type: EXPERIMENTAL
Intervention: Glu-OC in hemodialysis patients
Number of subjects: 68
Study 24455828 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-OC in hemodialysis patients
Number of subjects: 68